MetAlert makes GPS tracking devices primarily for people with cognitive disorders — Alzheimer's, dementia, and autism — who are at risk of wandering. The flagship product is the GPS SmartSole, a shoe insole with an embedded GPS and cellular tracker that caregivers monitor via a smartphone app or web portal. The insole form factor is central to the product's appeal: patients with cognitive impairment are often resistant to wearing unfamiliar devices, so a discreet, invisible design matters. MetAlert sells direct-to-consumer online, through retailers, and via a B2B sales team targeting assisted living facilities, senior care homes, schools, NGOs, and government agencies. The company also sells to the U.S. military and law enforcement, and distributes through international partners in 40+ countries. MetAlert's second business unit, acquired in 2023, sells GPS-enabled gun safety devices under the MyGunAlert brand. Revenue comes from one-time hardware sales, recurring subscriptions ($2–$35/month per device), IP licensing from a 23-patent portfolio, and professional services. The subscription stream is the most strategically important, as each device sold ideally converts into a long-term subscriber. A meaningful growth lever is insurance reimbursement: SmartSoles are partially or fully reimbursable through Medicaid, Medicare, or insurance in 11 U.S. states and several countries. MetAlert is a small company with fewer than a dozen employees and outsources manufacturing and connectivity.